glp-1 agonists tirzepatide Unveiling Tirzepatide's Therapeutic Spectrum: A Dual GIP/GLP-1 Agonist Targeting Metabolic, Neurological, and Cardiovascular Health GLP-1 Receptor Agonists - Mechanisms

Semaglutide 2.4mg once weekly, a subcutaneously administered GLP-1 RA approved for obesity treatment in 2021, results in 1517% mean weight loss (WL) with evidence of cardioprotection

GLP-1 therapy is a proven tool for weight management and metabolic health, but side effects can interfere with consistency

However, because federal law does not require state-licensed pharmacies that are not outsourcing facilities to submit adverse events to FDA, many cases are likely going undocumented.FDA has also warned companies that have illegally sold unapproved drugs containing semaglutide, tirzepatide or retatrutide that are falsely labeled for research purposes or not for human consumption. These products have been sold directly to consumers for human use with dosing instructions

Semaglutide is a once weekly subcutaneous injection, gradually titrated by your provider and documented in your patient portal

ProAct Pharmacy Benefit Management Solutions